US Edition
News from Pompe Disease News
Top Pompe Disease News News
Italy · ItalyLong-term use of Myozyme (alglucosidase alfa), marketed as Lumizyme in the U.S., helped individuals with late-onset Pompe disease (LOPD) maintain their ability to walk and breathe, while remaining generally safe and well tolerated over 15 years, according to a study in Italy. While responses varied, fewer than expected required ventilation and patients lived longer than if the disease had followed its natural course, suggesting long-term benefit…Read Article
Myozyme helps LOPD patients walk, breathe over long term: Study
Italy · ItalyA man was diagnosed with late-onset Pompe disease (LOPD) after prenatal genetic counseling, even though he exhibited no symptoms. “This example stresses the importance of pretest consultation and the relevance of clinical and ethical implications during prenatal genetic testing for the whole family group,” scientists wrote. His condition was described in “Case Report: Incidental late-onset Pompe disease diagnosis in a man with no clinical and in…Read Article
